Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or OpenAthens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Published: February 2010

Open Access Gateway

Genital Infection as a First Sign of Acute Myeloid Leukemia

Oiso N.a · Rai S.b · Kawara S.a · Tatsumi Y.b · Kawada A.a

Author affiliations

Departments of aDermatology, and bHematology, Kinki University School of Medicine, Osaka-Sayama, Japan

Corresponding Author

Naoki Oiso

Department of Dermatology

Kinki University School of Medicine, 377-2 Ohno-Higashi

Osaka-Sayama, Osaka 589-8511 (Japan)

Tel. +81 721 29 1121, Fax +81 721 28 3550, E-Mail naoiso@med.kindai.ac.jp

Related Articles for ""

Case Rep Dermatol 2010;2:18–21

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Fournier’s gangrene is a life-threatening disorder caused by aerobic and anaerobic bacterial infection. We report a case of genital infection as the initial warning sign of acute myeloid leukemia. We were able to prevent progression to Fournier’s gangrene in our patient by immediate intensive therapy with incision, blood transfusions and intravenous administration of antibiotics. This case suggests that hematologists and dermatologists should keep in mind that genital infection can be a first sign of hematologic malignancy.

© 2010 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Published: February 2010

Published online: February 06, 2010
Issue release date: January – April

Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 1

eISSN: 1662-6567 (Online)

For additional information: https://www.karger.com/CDE

Open Access License / Drug Dosage / Disclaimer

Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.